SWTX SpringWorks Therapeutics, Inc.
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
$69.35 -5.38 (-7.20%)
As of 03/04/2021 15:59:54 EST IEX book CBOE book
Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
01/04/1999
48,976,123
293,916
$3,659,985,672
0.00%
SEC Edgar Online
10-Q
10-K
85205L107
US85205L1070
BGMGM89
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
01/04/1999
48,976,123
293,916
$3,659,985,672
0.00%
SEC Edgar Online
10-Q
10-K
85205L107
US85205L1070
BGMGM89
Valuation (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
9.58
0.00
-26.79%
0.00%
9.58
0.00
-26.79%
0.00%